OncoSec Medical Aktie [WKN DE: A14TG5 / ISIN: US68234L2079]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu OncoSec Medical Inc

22.05.19		5 Top Losers In Pharma Sector (BCRX, ONCS, OCUL...) (RTTNews)
07.11.18		ONCS Hits New Low, AAC Trims Revenue Outlook, NVRO Down 45% YTD (RTTNews)
23.10.18		PETX On The Move, TTOO To Report Q3 Results On Nov.1, CLGN Inks Deal With UTHR (RTTNews)
08.06.18		Impartner Continues Rapid Expansion of Channel Management Technology Portfolio with Announcement of New Acquisition (PR Newswire)
04.06.18		OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting (PR Newswire)
01.06.18		Southwest Gas Holdings, Inc. Announces Filing of Nevada General Rate Case and Approval of Mesquite Expansion (PR Newswire)
24.05.18		Alicia Silverstone, Dave Asprey, angel Kyodo williams, Sally Kohn and more added to Wanderlust's Wellspring Conference (PR Newswire)
08.05.18		OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer (PR Newswire)
03.05.18		OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference (PR Newswire)
26.04.18		OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting (PR Newswire)
16.04.18		OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018 (PR Newswire)
03.04.18		OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting (PR Newswire)
20.03.18		OncoSec Announces Strategic Relocation Of Office And Laboratories (PR Newswire)
16.03.18		OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference (PR Newswire)
15.03.18		OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018 (PR Newswire)
12.03.18		OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer (PR Newswire)
12.03.18		EPIC's Chuck Simpson to Present on Hazard Recognition at Arklatex ASSE Chapter Meeting (PR Newswire)
16.01.18		OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors (PR Newswire)
08.01.18		Royole to Introduce Smart Writing Pad at CES 2018 (PR Newswire)
03.01.18		OncoSec Provides 2018 Business Outlook (PR Newswire)
14.12.17		OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab (PR Newswire)
05.12.17		OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer (PR Newswire)
28.11.17		OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform (PR Newswire)
14.11.17		FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz (RTTNews)
13.11.17		OncoSec Receives $9.3 Million Warrant Exercise (PR Newswire)
09.11.17		OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 (PR Newswire)
08.11.17		OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at... (PR Newswire)
07.11.17		OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company (PR Newswire)
25.10.17		OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 (PR Newswire)
19.10.17		OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder... (PR Newswire)
13.10.17		OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017 (PR Newswire)
12.10.17		OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting... (PR Newswire)
11.10.17		OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 (PR Newswire)
10.10.17		OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab) (PR Newswire)
04.10.17		EPIC adds Broker/Producer Tim House in Fresno (PR Newswire)
27.09.17		OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy (PR Newswire)
26.09.17		OncoSec to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
06.09.17		OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences (PR Newswire)
05.09.17		OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors (PR Newswire)
19.06.17		MVP American Securities Promotes Brandon Welch to Managing Director, Capital Markets (PR Newswire)
12.06.17		OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. (PR Newswire)
09.06.17		D-Day For CHRS, ENDO Pained, FDA Lifts Clinical Hold On INO's VGX-3100 Trial (RTTNews)
16.05.17		Gainers & Losers Of May 15: CBMG, ETRM, ALNY, EGRX, ONCS... (RTTNews)
11.05.17		OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017 (PR Newswire)
10.05.17		OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma (PR Newswire)
02.05.17		OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017 (PR Newswire)
02.05.17		How These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and OncoSec Medical (PR Newswire)
03.04.17		OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting (PR Newswire)
28.03.17		OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017 (PR Newswire)
23.03.17		Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 15:04
Kaufwert:	EUR
	Hinzufügen Speichern